Management of Hyperkalemia: An Update for the Internist

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Hyperkalemia is a critical electrolyte imbalance, frequently seen in chronic kidney disease (CKD) patients.
• Severe hyperkalemia poses significant risks, including life-threatening electrophysiological disturbances, necessitating emergency intervention.
• Current management often requires discontinuing beneficial medications like renin-angiotensin-aldosterone system (RAAS) inhibitors, creating a clinical dilemma.

Purpose of the Study:

• To review the pathophysiology, epidemiology, and management strategies for hyperkalemia.
• To highlight the clinical challenge of managing hyperkalemia in patients requiring RAAS inhibitors.
• To discuss novel potassium-binding therapies and their potential impact on patient care.

Main Methods:

• Literature review focusing on potassium metabolism, hyperkalemia, and current/emerging treatments.
• Analysis of the role of RAAS inhibitors in cardiovascular and renal disease.
• Examination of the mechanisms and clinical data of new potassium-lowering agents.

Main Results:

• Hyperkalemia management is complex, particularly when balancing the need for RAAS inhibitors.
• Two new potassium-binding medications show promise for managing both acute and chronic hyperkalemia.
• These novel therapies may enable continued use of RAAS inhibitors in susceptible patients.

Conclusions:

• New potassium binders offer a potential solution to the clinical compromise posed by hyperkalemia management.
• These agents could improve outcomes by allowing patients to remain on beneficial RAAS inhibitor therapy.
• Further research and clinical integration of these therapies are anticipated.